505884126 01/27/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5930951

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TERNS PHARMACEUTICALS, INC.	01/16/2020

RECEIVING PARTY DATA

Name:	TERNS, INC.	
Street Address:	1065 E. HILLSDALE BLVD., SUITE 100	
City:	FOSTER CITY	
State/Country:	CALIFORNIA	
Postal Code:	94404	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16549979

CORRESPONDENCE DATA

Fax Number: (650)494-0792

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (650) 813-5662 Email: ebowers@mofo.com Correspondent Name: JANE KUZELKA

Address Line 1: MORRISON & FOERSTER LLP

Address Line 2: 755 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304-1018

ATTORNEY DOCKET NUMBER:	79290-20008.00
NAME OF SUBMITTER:	JANE KUZELKA
SIGNATURE:	/Jane Kuzelka/
DATE SIGNED:	01/27/2020

Total Attachments: 2

source=79290-20008.00 Terns Pharma to Terns Inc#page1.tif source=79290-20008.00 Terns Pharma to Terns Inc#page2.tif

PATENT REEL: 051632 FRAME: 0806 505884126

Attorney Docket No.: 79290-20008.00

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor

Terns Pharmaceuticals, Inc.

Address:

P.O. Box 61

George Town, Grand Cayman, Cayman Islands KY1-1102

A juristic entity duly organized under and pursuant to the laws of: Cayman Islands

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the U.S. patent application identified below:

Serial No.: 16/549,979 Filing Date: August 23, 2019

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

This Assignment is to:

Assignee:

Terns, Inc.

Address:

1065 E. Hillsdale Blvd, Suite 100

Foster City, California 94404 United States of America

A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent application and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

- Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all non-provisionals, divisions, continuations, and continuations in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other postgrant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
- Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.
- 3. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States

sf-4156961

Attorney Docket No.: 79290-20008.00

Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: 1/16/2020

Signature:

Name: Weidong Zhong

Title: CEO

Company: Terns Pharmaceuticals, Inc.

ASSIGNEE:

Date: 1/16/220

Signature: ..

Name: Morsten Krichberg

Title: SQ Director

Company: Tems, Inc.

sf-4156961